Schadendorf, D., Dummer, R., Hauschild, A., Santinami, M., Atkinson, V., Mandala, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., Mortier, L., Robert, C., Schachter, J., Ortmann, C.-E., de Jong, E., Gasal, E., Kefford, R., Kirkwood, J.M. and Long, G.V. 2019. Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo. SKIN The Journal of Cutaneous Medicine. 3, (Nov. 2019), S53. DOI:https://doi.org/10.25251/skin.3.supp.53.